BOSTON and SYDNEY — 18 May 2017 — GI Dynamics®, Inc. (ASX: GID) (the Company) will hold its 2017 Annual Meeting of Stockholders on 22 May 2017, at 6:00 p.m., United States Eastern Daylight Time, (23 May 2017, at 8:00 a.m., Australian Eastern Standard Time) at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111.
Immediately following the Annual Meeting of Stockholders, Company management will provide a corporate update.
If not attending in person, the meeting and corporate update can be accessed through a teleconference line.
Accessing the Annual Meeting of Stockholders and Corporate Update via the teleconference line:
For those preferring to listen by telephone, please dial-in five minutes prior to the start of the call. Regional dial-in numbers are as follows:
United States callers please dial toll-free (877) 407-6184
Australia callers please dial toll-free 1 (800) 687-004
United Kingdom callers please dial toll-free 0 (800) 756-3429
International callers please dial (201) 389-0877
About GI Dynamics
GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier, the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com.
This announcement contains forward-looking statements concerning our expectations regarding the effect of the CE mark suspension, our ability to resolve nonconformance issues to the satisfaction of our notified body, and the timing of any reinstatement of our CE mark. These forward-looking statements are based on GI Dynamics management’s current estimates and expectations of future events as of the date of this announcement. Furthermore, the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to, risks associated with obtaining funding from third parties; the consequences of stopping the ENDO trial and the possibility that future clinical trials will not be successful or confirm earlier results; the timing and costs of clinical trials; the timing of regulatory submissions; the timing, receipt and maintenance of regulatory approvals; the timing and amount of other expenses; the timing and extent of third-party reimbursement; risks associated with commercial product sales, including product performance, competition, market acceptance of products, intellectual-property risk; risks related to excess inventory; and risks related to assumptions regarding the size of the available market, the benefits of our products, product pricing, timing of product launches, future financial results and other factors, including those described in our filings with the U.S. Securities and Exchange Commission. Given these uncertainties, one should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless we are required to do so by law.